Clinical trial · Interventional
Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option
A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Fewer than 15% of hepatoma patients are suitable candidates for surgical removal of their cancer. The purpose of this protocol is to provide supervised access at Oregon Health and Science University to Y-90 treatment to provide these patients access to an alternate therapy. The radioactive beads are placed directly near or into the liver tumor with the intention of destroying the tumor cells.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatoma | Hepatocellular Carcinoma | ALIAS | 0.90 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Yttrium 90 (TheraSphere) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Treatment
- description
- yttrium 90 (TheraSphere) administration
- interventionNames
- Device: Yttrium 90 (TheraSphere)
Primary outcomes (1)
- measure
- Tumor response after treatment based on tumor marker and lab results, CT scan and patient's symptoms.
- timeFrame
- 2 weeks, 1 month and then every 3 months
- description
- Tumors will decrease in size
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of HCC * Cancer is unresectable * ECOG Score 0-2 * Age of 18 yrs or over * Able to give consent Exclusion Criteria: * Contraindication to angiography and selective visceral catheterization * Portal hypertension with portal venous shunt away from the liver * Evidence of potential delivery of \> 16.5 mCi of radiation to the lungs * Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow * Significant extrahepatic disease representing an imminent life-threatening outcome * Severe liver dysfunction or pulmonary insufficiency * Active uncontrolled infection * Significant underlying medical or psychiatric illness * Pregnancy
References
Publications (0)
Data not yet available